Pharmaceutical and Biotechnology Companies Are Researching and Testing New Delivery Methods for Protein Drugs.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c67766) has announced the addition of new Decision Resources report Evolving Approaches for Protein Drug Delivery to their offering. Despite their remarkable success, protein drugs continue to suffer from important drawbacks, especially with respect to their delivery (subcutaneously or intravenously injected). Improvements in protein drug delivery will increase patient compliance and expand many drug markets. In addition, some new formulations may be patentable and can therefore extend a drug's life cycle. For these reasons, pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. are researching and testing new delivery methods for protein drugs. Get the Answers You Need to Shape Your Strategy Although protein-based drugs have had great commercial success, they still suffer from significant drawbacks, especially in the area of delivery. What are these drawbacks and what are the barriers for creating better protein drug delivery methods? -Many companies see the potential for improving the delivery methods for protein-based drugs. What companies are at the forefront of these improvements? -Researchers are approaching this opportunity from several different angles. Some companies are looking to modify drugs to improve pharmacokinetics while other companies are developing whole new technologies. What are the specific programs and development initiatives in place? What is the time line for the introduction of these improved drugs and/or delivery devices? Scope -Milestones: Recent approval of two large-molecule drugs (Fortical and Exubera) that do not require injection show proof-of-principle that noninjected protein and peptide drugs can be developed successfully. -Modification and discovery of protein drugs: Pegylation, fusion proteins, amino acid amino acid (əmē`nō), any one of a class of simple organic compounds containing carbon, hydrogen, oxygen, nitrogen, and in certain cases sulfur. These compounds are the building blocks of proteins. substitution or omission. -Discovery and development of novel modified proteins: novel pegylated protein drugs, novel fusion protein drugs, and novel bioengineered protein drugs. -Novel delivery methods in development: oral delivery, buccal buc·cal adj. 1. Of, relating to, adjacent to, or in the direction of the cheek. 2. Of or relating to the mouth cavity. buccal delivery, transdermal systems, subcutaneous subcutaneous /sub·cu·ta·ne·ous/ (sub?ku-ta´ne-us) beneath the skin. sub·cu·ta·ne·ous adj. Abbr. s.c., SQ Located, found, or placed just beneath the skin; hypodermic. implants, pulmonary delivery, intranasal in·tra·na·sal adj. Within the nose. delivery. -Outlook: status of current programs, anticipated product launches, outlook for protein drug market. Content Outline: Strategic Considerations Stakeholder stakeholder n. a person having in his/her possession (holding) money or property in which he/she has no interest, right or title, awaiting the outcome of a dispute between two or more claimants to the money or property. Implications Introduction Recent Milestones in Protein Drug Delivery Modification of Protein Drugs to Improve Pharmacokinetics Pegylation Fusion Proteins Amino Acid Substitution or Omission Discovery and Development of Novel Modified Proteins Novel Pegylated Protein Drugs Nektar Therapeutics Prolong Pharmaceuticals Novel Fusion Protein Drugs Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. Syntonix Pharmaceuticals Novel Bioengineered Protein Drugs Transdermal Systems and Subcutaneous Implants Transdermal Delivery Macrofl ux Apogee apogee (ăp`əjē), point farthest from the earth in the orbit of a body about the earth. See apsis. The farthest point. Technology Altea Therapeutics Peptide Chaperone chaperone /chap·er·one/ (shap´er-on) someone or something that accompanies and oversees another. molecular chaperone for Transdermal Delivery MicroCHIPS Oral and Buccal Delivery Unigene Emisphere Technologies Spherics spher·ics 1 n. (used with a sing. verb) 1. Spherical geometry. 2. Spherical trigonometry. Pharmaceuticals Generex DOR Dor or Dora, Canaanite seaport, ancient Palestine (modern Israel), N of Caesarea Palestinae. It was never a Jewish city but rather a Phoenician outpost. It was rebuilt by the Romans; still visible are the ruins of a temple and a theater. BioPharma Pulmonary and Intranasal Delivery Pulmonary Insulin Products in Late-Stage Development Alkermes/Eli Lilly MannKind Novo Nordisk Wikipedia is not the place for advertisement or self-advertising. Novo Nordisk (, NYSE: NVO) manufactures and markets pharmaceutical products and services. Founded in Denmark in 1923, the company has since become a world leader in diabetes care with the broadest Emerging Pulmonary and Intranasal Drug Delivery Systems Chrysalis chrysalis (krĭs`əlĭs): see pupa. Technologies Aegis Therapeutics Outlook for Protein Drug Delivery Tables: 1 Select Marketed Modifi ed Protein Drugs 2 Select Novel Modifi ed Protein Drugs in Development 3 Novel Transdermal Systems and Subcutaneous Implants 4 Novel Oral and Buccal Formulations of Protein and Peptide Drugs 5 Novel Pulmonary and Intranasal Formulations of Protein and Peptide Drugs Figures: 1 Anatomy of the Skin 2 MicroCHIPS's Implanted Drug Delivery Device 3 Schematic Representation of a Micelle micelle (mīsel´), n a space formed by the brush structure of fibrils in colloidal gels. The spaces are occupied by water in hydrocolloid impressions. and a Reverse Micelle Companies Mentioned: -Aegis Therapeutics -Aerogen -Alkermes -Altea Therapeutics -Alza -Amgen -Amylin Pharmaceuticals -Apogee Technology -Aradigm -Bayer -Biovitrum -Chrysalis Technologies -DOR BioPharma -Eli Lilly -Emisphere Technologies -Enzon -Generex -Georgia Tech Research Corporation -GlaxoSmithKline -Human Genome Sciences -Intranasal Therapeutics -Johnson & Johnson -Macroflux -MannKind -MicroCHIPS -Nautilus Biotech -Nektar Therapeutics -Novartis -Novo Nordisk -Pfizer -Prolong Pharmaceuticals -Roche -Sandoz -Sanofi-Aventis -Schering-Plough -Spherics Pharmaceuticals -Syntonix Pharmaceuticals -Takeda -UCB Pharma -Unigene Laboratories -Upsher-Smith -Wyeth Pharmaceuticals For more information visit http://www.researchandmarkets.com/reports/c67766 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion